Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Net sales	$ 3,719.1	$ 4,178.2
Biocon Biologics
Disaggregation of Revenue [Line Items]
Net sales		(164.8)
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,420.3	2,554.1
Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	136.1	390.8
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,162.7	1,233.3
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	417.9	440.1
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	202.7	207.8
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	144.3	171.7
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	115.0	129.8
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	95.8	88.8
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	88.8	85.2
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	64.6	77.5
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	56.5	73.1
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	72.7	74.7
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	46.7	53.0
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	36.6	41.8
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	39.7	40.0
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	53.2	44.0
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	47.0	43.7
Developed Markets (1) | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,232.0	1,298.7
Developed Markets (1) | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	129.9	364.1
Developed Markets (1) | Generics
Disaggregation of Revenue [Line Items]
Net sales	808.5	813.3
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	562.4	569.7
Greater China | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.0	0.0
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	2.2	3.4
JANZ | Brands
Disaggregation of Revenue [Line Items]
Net sales	190.3	249.0
JANZ | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	6.1	10.3
JANZ | Generics
Disaggregation of Revenue [Line Items]
Net sales	145.8	164.5
Emerging Markets (2) | Brands
Disaggregation of Revenue [Line Items]
Net sales	435.6	436.7
Emerging Markets (2) | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.1	16.4
Emerging Markets (2) | Generics
Disaggregation of Revenue [Line Items]
Net sales	206.2	252.1
Operating Segment | Developed Markets (1)
Disaggregation of Revenue [Line Items]
Net sales	2,170.4	2,476.1
Operating Segment | Greater China
Disaggregation of Revenue [Line Items]
Net sales	564.6	573.1
Operating Segment | JANZ
Disaggregation of Revenue [Line Items]
Net sales	342.2	423.8
Operating Segment | Emerging Markets (2)
Disaggregation of Revenue [Line Items]
Net sales	$ 641.9	$ 705.2